^
    Back
    Association details:
    Biomarker:TP53 wild-type
    Cancer:Small Lymphocytic Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Other recommended regimens…Bendamustine + rituximab...Chlorambucil + rituximab (category 2B)...High-dose methylprednisolone + rituximab...First-line therapy…Other recommended regimens…FR (fludarabine + rituximab).
    Secondary therapy:
    chlorambucil; methylprednisolone oral; bendamustine; fludarabine oral
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    CLL/SLL without del(17p)/TP53 mutation: First-line therapy...Other recommended regimens…Rituximab (category 3)